Pathstone Holdings
BMY icon

Pathstone Holdings’s Bristol-Myers Squibb BMY Stock Holding History

Pathstone Holdings’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.1M Buy
260,552
+33,627
+15% +$1.93M 0.04% 265
2026
Q1 		$13.8M Buy
226,925
+41,072
+22% +$2.39M 0.05% 243
2025
Q4 		$10M Sell
185,853
-22,578
-11% -$1.09M 0.04% 339
2025
Q3 		$9.4M Sell
208,431
-38,856
-16% -$1.81M 0.04% 355
2025
Q2 		$11.4M Buy
247,287
+30,634
+14% +$1.5M 0.05% 286
2025
Q1 		$13.2M Buy
216,653
+5,786
+3% +$337K 0.06% 249
2024
Q4 		$11.9M Buy
210,867
+21,917
+12% +$1.22M 0.05% 250
2024
Q3 		$9.78M Buy
188,950
+4,062
+2% +$191K 0.04% 328
2024
Q2 		$7.68M Sell
184,888
-28,081
-13% -$1.26M 0.03% 389
2024
Q1 		$11.5M Sell
212,969
-11,765
-5% -$599K 0.05% 266
2023
Q4 		$11.6M Buy
+224,734
New +$11.8M 0.06% 235

Other funds holding BMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Pathstone Holdings's BMY Position: Q2 2026 in Review

Pathstone Holdings increased its Bristol-Myers Squibb (BMY) stake by 15% in Q2 2026, buying an estimated $1.93M and bringing the position to 260,552 shares worth $15.1M. The position accounts for 0.04% of the portfolio, ranked #265.

Pathstone Holdings first reported a position in BMY in Q4 2023 and has held it in 11 quarters since. 2,529 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Pathstone Holdings held 260,552 shares of Bristol-Myers Squibb worth $15.1M as of Q2 2026.
  • Pathstone Holdings bought 33,627 Bristol-Myers Squibb shares in Q2 2026, an estimated $1.93M.
  • Bristol-Myers Squibb made up 0.04% of Pathstone Holdings's portfolio in Q2 2026, its #265 holding.
  • Pathstone Holdings first reported a position in Bristol-Myers Squibb in Q4 2023 and has held it in 11 quarters since.
  • 2,529 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Pathstone Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.